NO20075945L - Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav - Google Patents

Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav

Info

Publication number
NO20075945L
NO20075945L NO20075945A NO20075945A NO20075945L NO 20075945 L NO20075945 L NO 20075945L NO 20075945 A NO20075945 A NO 20075945A NO 20075945 A NO20075945 A NO 20075945A NO 20075945 L NO20075945 L NO 20075945L
Authority
NO
Norway
Prior art keywords
active vitamin
treatment
imitators
amelioration
radiotherapy
Prior art date
Application number
NO20075945A
Other languages
English (en)
Inventor
John G Curd
Bradford S Goodwin
Jeffrey L Cleland
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Publication of NO20075945L publication Critical patent/NO20075945L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelse vedrører en fremgangsmåte for å forebygge, behandle eller lindre lungeforstyrrelser i en pasient mottaende ett kjemoterapeutisk eller radioterapeutisk middel eller behandling, omfattende å administrere til pasienten en farmasøytisk sammensetning omfattende en effektiv mengde av aktiv vitamin D-forbindelse, eller en imitasjon derav. I henhold til oppfinnelsen kan den aktive vitamin D-forbindelsen, eller imitasjonen derav, administreres ved HDPA slik at høye doser av den aktive vitamin D-forbindelsen kan administreres til et dyr uten å indusere alvorlig symptomatisk hyperkalsemi.
NO20075945A 2005-04-22 2007-11-19 Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav NO20075945L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67381205P 2005-04-22 2005-04-22
US72113505P 2005-09-28 2005-09-28
PCT/US2006/015281 WO2006116204A1 (en) 2005-04-22 2006-04-24 Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof

Publications (1)

Publication Number Publication Date
NO20075945L true NO20075945L (no) 2008-01-16

Family

ID=37215072

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075945A NO20075945L (no) 2005-04-22 2007-11-19 Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav

Country Status (11)

Country Link
US (1) US20090069276A1 (no)
EP (1) EP1871386A1 (no)
JP (1) JP2008538580A (no)
KR (1) KR20080028860A (no)
AU (1) AU2006239883A1 (no)
BR (1) BRPI0610077A2 (no)
CA (1) CA2606517A1 (no)
IL (1) IL186805A0 (no)
MX (1) MX2007013029A (no)
NO (1) NO20075945L (no)
WO (1) WO2006116204A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
US8501717B2 (en) 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
EP3028743A3 (en) * 2008-03-05 2017-01-25 Vicus Therapeutics, LLC Compositions for mucositis and oncology therapies
EP2393494A1 (en) * 2009-01-27 2011-12-14 Berg Biosystems, LLC Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
GB2502032B (en) * 2011-03-02 2015-03-04 D3 Pharma Ltd Stable Vitamin D3 Composition
US20220273614A1 (en) * 2019-07-31 2022-09-01 Ronald HUNNINGHAKE Intravenous vitamin c therapy protocol for the treatment of cancer
ES2862462B2 (es) * 2020-04-06 2023-04-27 Servicio Andaluz De Salud Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192664A (en) * 1989-03-22 1993-03-09 Peter K. T. Pang Parathyroid hypertensive factor, antibodies and uses thereof
US5350745A (en) * 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure
WO1995001960A1 (en) * 1993-07-09 1995-01-19 Laboratoire Theramex S.A. Novel structural analogues of vitamin d
AU726659B2 (en) * 1996-04-09 2000-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
US6573256B2 (en) * 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
IT1291141B1 (it) * 1997-04-16 1998-12-29 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente una alcanoil l-carnitina, atta a stimolare la moltiplicazione e la crescita degli osteoblasti
WO1998051678A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF
AU728037B2 (en) * 1997-05-22 2001-01-04 Cephalon, Inc. Vitamin D analogues and their neuronal effects
CA2326117A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
US6248127B1 (en) * 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
GB9819764D0 (en) * 1998-09-10 1998-11-04 Oxagen Limited Method
EP1123921A4 (en) * 1998-10-23 2003-08-20 Teijin Ltd VITAMIN D 3 DERIVATIVES? AND MEDICINES FOR INFLAMMATORY RESPIRATORY DISEASES CONTAINING THEM
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
WO2001040177A2 (en) * 1999-12-02 2001-06-07 Women And Infants Hospital Esters of vitamin d3 and uses thereof
US6395784B1 (en) * 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
CA2528519A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2528378A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
AU2004247109A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of cancer with active vitamin D compounds in combination with radiotherapeutic agents and treatments
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease

Also Published As

Publication number Publication date
CA2606517A1 (en) 2006-11-02
JP2008538580A (ja) 2008-10-30
EP1871386A1 (en) 2008-01-02
US20090069276A1 (en) 2009-03-12
WO2006116204A1 (en) 2006-11-02
MX2007013029A (es) 2008-01-11
BRPI0610077A2 (pt) 2010-05-25
IL186805A0 (en) 2008-02-09
KR20080028860A (ko) 2008-04-02
AU2006239883A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
Lin et al. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study
NO20075945L (no) Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav
NO20081863L (no) Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
Li et al. Pharmacological studies on the sedative and hypnotic effect of salidroside from the Chinese medicinal plant Rhodiola sachalinensis
MX2010003556A (es) Regimen de tratamiento para trastornos proliferantes.
WO2014160216A3 (en) Dual targeting anticancer agents
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
EP4233913A3 (en) Improved bromocriptine formulations
Wang et al. Anti‑inflammatory effect of delphinidin on intramedullary spinal pressure in a spinal cord injury rat model
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
NO20064753L (no) Kombinasjonsterapi
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
JP2019529569A5 (no)
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
Chung et al. Anticancer and Antineurodegenerative effects of Ginsenosides
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
Lee et al. Saikosaponin D Inhibits Lung Metastasis of Colorectal Cancer Cells by Inducing Autophagy and Apoptosis
JPWO2020009950A5 (no)
Davis et al. Fingolimod is cytotoxic in acute myeloid leukemia independent of additional chemotherapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application